Trial reportJournal of the American Heart Association2025
Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02993406 (A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
Who cites it
4 citing papers in PubMed.
- Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- Bempedoic Acid: From Guidelines to the Real World.Journal of lipid and atherosclerosis · 2026Review
- Perspectives on Bempedoic Acid, ATP-citrate lyase inhibitor: Targeting Lipid Metabolism and Inflammation.Journal of atherosclerosis and thrombosis · 2026Review
- Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.Journal of clinical medicine research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and hypercholesterolemia independently increase cardiovascular disease risk. This analysis evaluated the efficacy and safety of bempedoic acid in people with obesity participating in the CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen) Outcomes trial.
methodsCLEAR Outcomes randomized 13 970 patients to daily bempedoic acid 180 mg or placebo. Exploratory outcomes including major adverse cardiovascular events-4 (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization), low-density lipoprotein cholesterol, hs-CRP (high-sensitivity C-reactive protein), weight change, and safety were assessed over a median of 40.7 months in 6177 patients with baseline body mass index ≥30 kg/m
resultsIn people with obesity, bempedoic acid resulted in placebo-corrected reductions in low-density lipoprotein cholesterol of -22.5% and hs-CRP of -23.2% at 6 months. Bempedoic acid treatment resulted in a major adverse cardiovascular events-4 reduction of 23% (hazard ratio [HR], 0.77 [95% CI, 0.67-0.89]) versus placebo. Nonfatal and fatal MI were reduced by 32% (HR, 0.68 [95% CI, 0.53-0.86]), coronary revascularization was reduced by 24% (HR, 0.76 [95% CI, 0.63-0.92]), and fatal and nonfatal stroke were reduced by 36% (HR, 0.64 [95% CI, 0.45-0.89]) compared with placebo. At month 36, mean±SD change in weight from baseline was -2.3 (6.3) kg for bempedoic acid and -1.4 (6.1) kg for placebo. Adverse events were reported in 87.4% of bempedoic acid patients and 86.7% of placebo patients. The mean±SD change in uric acid at 6 months was 0.81 (1.26) mg/dL for bempedoic acid versus -0.04 (1.05) mg/dL for placebo.
conclusionsAmong people with obesity, bempedoic acid reduced major adverse cardiovascular events, low-density lipoprotein cholesterol, and hs-CRP, with a safety profile consistent with previous reports. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02993406.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.